机票价格趋于两极分化 买机票将成技术活
Jarushka Naidoo shared on X:
“Intracranial activity of Tarlatamab in 2L SCLC in Ph I DeLLphi-300 Trial:
– 152 patients, mfollow
-up 12.1m
– intracranial ORR 62.5% (all prior RT)
– mOS 17.5m, ORR 25%
Important data, now to make this easier to give to patients.”
Authors:?Afshin Dowlati, Horst-Dieter Hummel,?Stephane Champiat,?Maria Eugenia Olmedo,?Michael Boyer,?Kai He,?Neeltje Steeghs,?Hiroki Izumi,?Melissa L. Johnson,?Tatsuya Yoshida, Hasna Bouchaab,?Hossein Borghaei,?Enriqueta Felip,?Philipp J. Jost,?Shirish Gadgeel, Xi Chen, Youfei Yu,?Pablo Martinez,?Amanda Parkes,?Luis?Paz-Ares,
For more posts by Jarushka Naidoo, visit oncodaily.com
Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.
She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023